血浆凝血酶调节蛋白检测的临床研究(英文)  

Clinical Study of Plasma Thrombomodulin Detection

作　　者：卢兴国[1] 童杰峰[1] 张强[1] 张茂[1] 沈汉超[1] 张佩利[1] 曹越兰[1] 徐根波[1] 龚旭波[1] 

机构地区：[1]浙江大学医学院附属第二医院血液科,杭州310009

出　　处：《中国实验血液学杂志》2007年第1期112-116,共5页Journal of Experimental Hematology

摘　　要：为了探讨血浆凝血酶调节蛋白(PTM)检测的临床价值,用ELISA法测定979例患者的PTM,并选择60名健康人作为对照。结果表明:对照组PTM水平为20.40±7.72μg/L,无性别和年龄差异。在疾病组中,原发性慢性肾小球疾病肾功能衰竭(CRF)组PTM水平高于无CRF组,败血症组PTM水平高于非败血症组,多脏器功能衰竭(MOF)组PTM水平高于无MOF组(P<0.01);以>70、>50和>40μg/L为标准,分别预示CRF、败血症和MOF的灵敏度为85.7%、86.6%和77.8%,特异性为82.4%、89.5%和77.3%,阳性预示值为77.8%、76.5%和73.7%。系统性红斑狼疮(SLE)尿蛋白阳性组PTM水平高于阴性组;糖尿病并发症组的PTM水平高于无并发症组,并发微血管病变组的PTM水平高于大血管病变组(P均<0.01);以PTM高于正常上限值(>35.54μg/L)为标准,预示SLE尿蛋白阳性临床肾损害、糖尿病并发症和微血管病变的灵敏度为77.8%、53.4%和71.2%,特异性为92.3%、97.1%和97.1%,阳性预示值为93.3%、98.6%和97.9%。急性白血病(AL)和多发性骨髓瘤(MM)初诊时PTM升高,两病并发肾衰时极度升高(P<0.01)。动态检测多发伤、脑卒中急性期和恢复期、AL和MM化疗前后、癌症术前后PTM水平与病情变化相关。以微血管病变为主要疾病的PTM水平高于大血管病变疾病(P<0.01),以高于正常上限值为标准,微血管病变疾病的灵敏度为77.7%、特异性71.2%,阳性预示值75.6%。结论:PTM水平是评估微血管病变疾病的良好指标,也是预警或评估疾病严重程度及其演变或疗效观察的有用指标。The purpose of this study was to investigate the clinical value of plasma thrombomodulin （PTM） in different diseases or in different severity or complications of diseases, PTM in 979 patients and 60 healthy controls was determined by ELISA method. The results showed that the PTM level in the control group was 20.40 ± 7.72 μg/L, there was no difference in sex and ages. In chronic primary glomerular disease, the PTM level in chronic renal failure （CRF） group was higher than that in non-CRF group （P 〈0.01 ）. PTM level 〉 70 μg/L was defined as its positive criterion. The sensitivity, specificity and positive predictive value in PTM were 85.7%, 82.4% and 77.8% respectively. The PTM level in septemia group was higher than that in non-septemia group （ P 〈 0.01 ）, the sensitivity, specificity and positive predictive value were 86.6%, 89.5% and 76.5% respectively （ 〉50 μg/L as its positive criterion）. With respect of multiple trauma, the PTM level in multiple organ failare （MOF） group was higher than that in non-MOF group （ P 〈0.01 ）, while the sensitivity, specificity and positive predictive value were 77.8%, 77.3% and 73.7% respectively （ 〉40 μg/L as its positive criterion）. For systemic lupus erythematosus （SLE）, the PTM level in the patients with albuminuria was higher than that in the patients without albuminuria （P 〈0.01 ）, and the sensitivity, specificity and positive predictive value were 77.8%, 92.3% and 93.3% respectively （ 〉35.54 μg/L as its positive criterion）. For diabetes, the PTM level in complication group was higher than that in group without complications, the sensitivity, specificity and positive predictive value were 53.4% ,97.1% and 98.6% respectively （ 〉 35.54 μg/L as its positive criterion）. The PTM level in microangiopathy group was higher than that in macroangiopathy group （ P 〈 0.01 ）. The sensitivity, specificity and positive predictive value were 71.2%, 97.1% and 97.9% respectively. Acute leukemia （AL） and multip

关 键 词：血浆凝血酶调节蛋白 疾病严重程度/并发症 微血管病变 大血管病变 

分 类 号：Q556[生物学—生物化学]